Analysts See $-0.64 EPS for Arena Pharmaceuticals, Inc. (ARNA)

February 19, 2018 - By Peter Erickson

 Analysts See $ 0.64 EPS for Arena Pharmaceuticals, Inc. (ARNA)

Analysts expect Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report $-0.64 EPS on March, 13.They anticipate $2.24 EPS change or 140.00 % from last quarter’s $1.6 EPS. After having $-0.65 EPS previously, Arena Pharmaceuticals, Inc.’s analysts see -1.54 % EPS growth. The stock increased 0.07% or $0.03 during the last trading session, reaching $40.8. About 366,253 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined 11.92% since February 19, 2017 and is downtrending. It has underperformed by 28.62% the S&P500.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Coverage

Among 8 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Arena Pharmaceuticals had 16 analyst reports since October 28, 2015 according to SRatingsIntel. The company was maintained on Thursday, January 4 by Cantor Fitzgerald. Citigroup maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Wednesday, July 12. Citigroup has “Buy” rating and $37 target. As per Wednesday, November 11, the company rating was maintained by RBC Capital Markets. Leerink Swann maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Wednesday, January 17. Leerink Swann has “Buy” rating and $56.0 target. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Hold” rating given on Tuesday, August 8 by Needham. The company was maintained on Tuesday, July 11 by Cantor Fitzgerald. The firm earned “Buy” rating on Wednesday, November 8 by Cantor Fitzgerald. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, June 29. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Wednesday, July 19 with “Buy” rating. The rating was maintained by WallachBeth Capital on Wednesday, October 28 with “Buy”.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.60 billion. The company's proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

More notable recent Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news were published by: Prnewswire.com which released: “Arena Pharmaceuticals Announces Changes to Board of Directors” on February 16, 2018, also Prnewswire.com with their article: “Arena Pharmaceuticals to Present at Upcoming Investor Conferences” published on February 06, 2018, Valuewalk.com published: “Genocea Biosciences, Inc. (GNCA) gets new 8.9% owner; Arena Pharmaceuticals …” on January 29, 2018. More interesting news about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) were released by: Seekingalpha.com and their article: “Key events next week – healthcare” published on February 16, 2018 as well as Prnewswire.com‘s news article titled: “Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and …” with publication date: January 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.